SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-381105"
 

Search: onr:"swepub:oai:DiVA.org:uu-381105" > Posterior reversibl...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005015naa a2200565 4500
001oai:DiVA.org:uu-381105
003SwePub
008190405s2019 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:140589202
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3811052 URI
0247 a https://doi.org/10.1002/pbc.275942 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1405892022 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Anastasopoulou, Stavroulau Karolinska Institutet4 aut
2451 0a Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia :b Clinical characteristics, risk factors, course, and outcome of disease
264 c 2018-12-27
264 1b WILEY,c 2019
338 a print2 rdacarrier
520 a Background: Posterior reversible encephalopathy syndrome (PRES) is a distinct entity with incompletely known predisposing factors. The aim of this study is to describe the incidence, risk factors, clinical course, and outcome of PRES in childhood acute lymphoblastic leukemia (ALL).Procedure: Patients aged 1.0 to 17.9 years diagnosed with ALL from July 2008 to December 2015 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol were included. Patients with PRES were identified in the prospective NOPHO leukemia toxicity registry, and clinical data were collected from the medical records.Results: The study group included 1378 patients, of whom 52 met the criteria for PRES. The cumulative incidence of PRES at one month was 1.7% (95% CI, 1.1-2.5) and at one year 3.7% (95% CI, 2.9-4.9). Older age (hazard ratios [HR] for each one-year increase in age 1.1; 95% CI, 1.0-1.2, P = 0.001) and T-cell immunophenotype (HR, 2.9; 95% CI, 1.6-5.3, P = 0.0005) were associated with PRES. Central nervous system (CNS) involvement (odds ratios [OR] = 2.8; 95% CI, 1.2-6.5, P = 0.015) was associated with early PRES and high-risk block treatment (HR = 2.63; 95% CI, 1.1-6.4, P = 0.033) with late PRES. At follow-up of the PRES patients, seven patients had epilepsy and seven had neurocognitive difficulties.Conclusion: PRES is a neurotoxicity in the treatment of childhood ALL with both acute and long-term morbidity. Older age, T-cell leukemia, CNS involvement and high-risk block treatment are risk factors for PRES.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a ALL
653 a neuroimaging
653 a PRES
653 a seizures
7001 a Eriksson, Mats A.u Karolinska Institutet4 aut
7001 a Heyman, Matsu Karolinska Institutet4 aut
7001 a Wang, Chenu Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden4 aut
7001 a Niinimäki, Riittau Oulu Univ Hosp, Dept Children & Adolescents, Oulu, Finland;Univ Oulu, PEDEGO Res Unit, Oulu, Finland4 aut
7001 a Mikkel, Sirjeu Univ Tartu, Dept Hematol & Oncol, Tartu, Estonia4 aut
7001 a Vaitkeviciene, Goda E.u Vilnius Univ Hosp Santaros Klin, Childrens Hosp, Vilnius, Lithuania;Vilnius Univ, Vilnius, Lithuania4 aut
7001 a Johannsdottir, Inga Mariau Oslo Univ Hosp, Dept Pediat Hematol Oncol, Oslo, Norway4 aut
7001 a Myrberg, Ida Hedu Karolinska Institutet4 aut
7001 a Jonsson, Olafur Gisliu Univ Iceland, Dept Pediat, Reykjavik, Iceland4 aut
7001 a Als-Nielsen, Bodilu Rigshosp, Univ Hosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark;Univ Copenhagen, Fac Med, Inst Clin Med, Copenhagen, Denmark4 aut
7001 a Schmiegelow, Kjeldu Rigshosp, Univ Hosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark;Univ Copenhagen, Fac Med, Inst Clin Med, Copenhagen, Denmark4 aut
7001 a Banerjee, Joannau Univ Helsinki, Childrens Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplanta, Helsinki, Finland;Helsinki Univ Hosp, Helsinki, Finland4 aut
7001 a Harila-Saari, Arja H.u Uppsala universitet,Barnneurologi/Barnonkologi4 aut0 (Swepub:uu)arjha456
7001 a Ranta, Susannau Karolinska Institutet4 aut
7102 a Karolinska Institutetb Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden4 org
7730 t Pediatric Blood & Cancerd : WILEYg 66:5q 66:5x 1545-5009x 1545-5017
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-381105
8564 8u https://doi.org/10.1002/pbc.27594
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:140589202

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view